Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SGP

SpyGlass Pharma Inc

Feb 11 • 03:42PM ET

28.64

+0.81 2.91 %

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	31.91M	Perf Week	-
Market Cap	913.90M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	9.37M	Perf Month	-
Enterprise Value	974.08M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	8.48%
Book/sh	-1.90	P/C	56.17	EPS next 5Y	-	ROE	-	52W High	32.44 -11.71%	Perf Year	-
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	20.16 42.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	5.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	-	SMA20	5.05%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	5.05%	Rel Volume	0.05	Prev Close	27.83
Employees	-	LT Debt/Eq	0.29	Earnings	-	SMA200	5.05%	Avg Volume	500.99K	Price	28.64
IPO	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	26,240	Change	2.91%

Feb-09-26 04:05PM

SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

(GlobeNewswire) +6.30%

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nielsen Kirk G.	Director	Feb 09 '26	Buy	16.00	165,000	2,640,000	3,310,619	Feb 10 06:09 PM
Vensana Capital I GP, LLC	10% Owner	Feb 09 '26	Buy	16.00	165,000	2,640,000	3,310,619	Feb 10 06:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGP

SpyGlass Pharma Inc

Upgrade your FINVIZ experience